Thermo Fisher Scientific (TMO)
(Delayed Data from NYSE)
$598.03 USD
-17.66 (-2.87%)
Updated Aug 5, 2024 04:00 PM ET
After-Market: $598.05 +0.02 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth C Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$598.03 USD
-17.66 (-2.87%)
Updated Aug 5, 2024 04:00 PM ET
After-Market: $598.05 +0.02 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth C Momentum D VGM
Zacks News
Thermo Fisher Scientific is a scientific instrument maker and a world leader in serving science. In Nov 2006, Thermo Fisher Scientific, Inc. was formed through the merger of Thermo Electron Corporation with Fisher Scientific International Inc. On Feb 3, 2014, Thermo Fisher acquired Life Technologies Corporation. Following the acquisition, the new reporting segments are: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Molecular Diagnostic Market Gains Momentum: 3 Stocks in Focus
by Sweta Jaiswal
Rising incidence of infectious diseases and increasing acceptance of companion diagnostics are driving the molecular diagnostics market.
Thermo Fisher (TMO) Scales a 52-Week High: What's Driving It?
by Zacks Equity Research
Thermo Fisher (TMO) sees strength in all end markets, categorized either by customer type or geography.
The Zacks Analyst Blog Highlights: Chevron, Amgen, Thermo Fisher, Estee Lauder and Delta Air Lines
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Chevron, Amgen, Thermo Fisher, Estee Lauder and Delta Air Lines
Thermo Fisher (TMO) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Thermo Fisher (TMO) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Top Stock Reports for Chevron, Amgen & Thermo Fisher
by Mark Vickery
Today's Research Daily features new research reports on 12 major stocks, including Chevron (CVX), Amgen (AMGN), and Thermo Fisher (TMO).
Here's Why You Should Hold on to Roper (ROP) Stock for Now
by Zacks Equity Research
Roper (ROP) stands to gain from acquired assets, healthy segmental business and operations in various markets. However, rising costs and buyout-related integration risks remain issues.
Stock Market News For Sep 10, 2018
by Zacks Equity Research
Markets ended sharply lower on Friday after President Donald Trump said that the United States was ready to move ahead with tariffs.
Thermo Fisher to Acquire BD's Advanced Bioprocessing Unit
by Zacks Equity Research
BD's (BDX) Advanced Bioprocessing business generates revenues worth $100 million annually. The unit will be integrated in the Thermo Fisher's (TMO) Life Sciences Solutions Segment.
Thermo Fisher (TMO) Up 0.1% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Thermo Fisher (TMO) reported earnings 30 days ago. What's next for the company? We take a look at earnings estimates for some clues.
Pacific Biosciences' Sequel Sees Solid Q2, Competition Rife
by Zacks Equity Research
Pacific Biosciences (PACB) gains from solid presence in Asia; competition likely to mar results.
Allscripts (MDRX) Q2 Earnings In Line, Revenues Top Estimates
by Zacks Equity Research
Allscripts (MDRX) gains from solid segmental performance in Q2; a decline in bookings discourages.
Zacks.com featured highlights include: Biogen, Thermo Fisher, HCA, Gilead and QUALCOMM
by Zacks Equity Research
Zacks.com featured highlights include: Biogen, Thermo Fisher, HCA, Gilead and QUALCOMM
CONMED (CNMD) Beats on Q2 Earnings, Raises 2018 Guidance
by Zacks Equity Research
CONMED (CNMD) sees solid domestic and international sales in Q2; raised guidance encourages.
Masimo (MASI) Beats on Q2 Earnings, Raises 2018 Guidance
by Zacks Equity Research
Masimo (MASI) gains from solid segmental performance in Q2; non-invasive technology continues to be in demand.
Becton, Dickinson (BDX) Earnings and Revenues Beat in Q3
by Zacks Equity Research
Becton, Dickinson (BDX) gains from solid segmental and geographical sales in Q3.
5 Cheap PEG Stocks Suitable for GARP Investors
by Zacks Equity Research
Although PEG is categorized under value investing, this strategy follows the principles of both growth and value investing.
The Zacks Analyst Blog Highlights: Amazon, Facebook, Thermo Fisher, Home Depot and Progressive
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Amazon, Facebook, Thermo Fisher, Home Depot and Progressive
Top Stock Reports for Amazon, Facebook & Thermo Fisher
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Amazon (AMZN), Facebook (FB) and Thermo Fisher (TMO).
Thermo Fisher (TMO) Beats on Q2 Earnings, Ups '18 EPS View
by Zacks Equity Research
Thermo Fisher (TMO) is performing well on the back of a series of product launches along with major progress in precision medicine initiatives.
Thermo Fisher Scientific (TMO) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Thermo Fisher (TMO) delivered earnings and revenue surprises of 4.56% and 2.75%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Thermo Fisher (TMO) Beats on Q2 Earnings & Sales Estimates
by Urmimala Biswas
Thermo Fisher (TMO) has launched innovative new products in the key technology platforms and also registered strong growth in Asia-Pacific and emerging markets, including China.
Medical Product Earnings Lineup for Jul 25: TMO, BSX & More
by Zacks Equity Research
The Medical product market further gains momentum on the back of a recent two-year suspension of the controversial 2.3% Medical Device tax.
Thermo Fisher (TMO) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
Thermo Fisher (TMO) continues with its impressive performance momentum across analytical instrument businesses witnessing escalating global demand.
Roper Technologies (ROP) to Divest Gatan Business for $925M
by Zacks Equity Research
Roper Technologies (ROP) agrees to divest its Pleasanton, CA-based Gatan business to Thermo Fisher Scientific (TMO), against roughly $925 million cash.
Thermo Fisher to Buy Gatan, Boost Electron Microscopy Suite
by Zacks Equity Research
Thermo Fisher (TMO) forges ahead with initiatives to strengthen foothold in the high-potential electron microscopy market.